CTLA4 and neoplasm: This is because targeting multiple inhibitory immune checkpoints concomitantly often induces stronger anti-tumor effects, which is why PD-1 and CTLA-4 ICI combinations are standard of care in patients with metastatic melanoma, advanced/recurrent NSCLC, malignant pleural mesothelioma, amongst others [157].